PAN: Macular Diseases (Medicare)

Not Funded
About
The PAN: Macular Diseases (Medicare) program provides crucial financial support for patients receiving treatment for specified macular diseases, ensuring access to a wide range of essential drug products such as Lucentis, Ozurdex, Iluvien, Eylea, Beovu, and more. By offering swift eligibility determinations and comprehensive assistance for drug costs, the PAN: Macular Diseases (Medicare) program significantly reduces the financial burden on patients and enhances their treatment accessibility.
Insurance requirements: Medicare / Medicaid
Enrollment Forms
Enrollment Form
Benefits
$2100 annual maximum benefit
Program Requirements
Valid only for residents in the US and Puerto Rico
Enrollment Required: Yes
Coverage Required: No
Needs Based: Yes
Activation Required: No
Program Details
Please note that this fund may cover offlabel drugs
Patients can either call (18663167263) or apply through selfservice patient portal
Provided patient completes application on self service portal or over the phone, eligibility determination takes less than one minute
Portal/representative will provide enrollment dates, the patient's PAN I.D. number and the available grant balance, allowing for medications to be dispensed
Patients will also receive approval letter and plastic pharmacy card within one week (provider will also receive letter)
Assistance begins on approval date and continues for 12 months
During initial eligibility period, eligible expenses incurred up to 90 days prior to approval date may also be submitted for reimbursement
All eligible expenses must be submitted within 120 days of the eligibility end date
Payment can be made to the patient, physician, pharmacy or health care provider
Patients are eligible for renewal at the end of their eligibility period if funds are available
Foundation will send a renewal application automatically if the program is accepting renewal patients
Patient may apply for a second grant during their eligibility period subject to availability of funding
Diagnosis Codes: ICD10: E08.311, E08.3211, E08.3212, E08.3213, E08.3219, E08.3311, E08.3312, E08.3313, E08.3319, E08.3411, E08.3412, E08.3413, E08.3419, E08.3511, E08.3512, E08.3513, E08.3519, E08.3521, E08.3522, E08.3523, E08.3529, E09.311, E09.3211, E09.3212, E09.3213, E09.3219, E09.3311, E09.3312, E09.3313, E09.3319, E09.3411, E09.3412, E09.3413, E09.3419, E09.3511, E09.3512, E09.3513, E09.3519, E09.3521, E09.3522, E09.3523, E09.3529, E10.311, E10.3211, E10.3212, E10.3213, E10.3219, E10.3311, E10.3312, E10.3313, E10.3319, E10.3411, E10.3412, E10.3413, E10.3419, E10.3511, E10.3512, E10.3513, E10.3519, E10.3521, E10.3522, E10.3523, E10.3529, E11.311, E11.3211, E11.3212, E11.3213, E11.3219, E11.3311, E11.3312, E11.3313, E11.3319, E11.3411, E11.3412, E11.3413, E11.3419, E11.3511, E11.3512, E11.3513, E11.3519, E11.3521, E11.3522, E11.3523, E11.3529, E13.3211, E13.3212, E13.3213, E13.3219, E13.3311, E13.3312, E13.3313, E13.3319, E13.3411, E13.3412, E13.3413, E13.3419, E13.3511, E13.3512, E13.3513, E13.3519, E13.3521, E13.3522, E13.3523, E13.3529, H18.551, H18.552, H18.553, H18.559, H35.30, H35.3110, H35.3111, H35.3112, H35.3113, H35.3114, H35.3120, H35.3121, H35.3122, H35.3123, H35.3124, H35.3130, H35.3131, H35.3132, H35.3133, H35.3134, H35.3190, H35.3191, H35.3192, H35.3193, H35.3194, H35.3210, H35.3211, H35.3212, H35.3213, H35.3220, H35.3221, H35.3222, H35.3223, H35.3230, H35.3231, H35.3232, H35.3233, H35.3290, H35.3291, H35.3292, H35.3293, H35.351, H35.352, H35.353, H35.359, H35.361, H35.362, H35.363, H35.369, H35.371, H35.372, H35.373, H35.379, H43.821, H43.822, H43.823, H43.829
Other Programs

Accessia Health: Inherited Retinal Diseases - Public Insurance: Waitlist

Medicare / Medicaid
Max Saving: $5000/year*

Genentech Patient Foundation

Commercially Insured
Medicare / Medicaid
Underinsured
Uninsured
Pay as low as
$0/ fill
Other Tools for Vabysmo